Background Abiraterone acetate became a referral treatment for metastatic castration-resistant prostate cancer (mCRPC) in a post-docetaxel setting despite a remarkable percentage of cardiovascular adverse events (AEs). As a consequence, the evaluation of cardiovascular safety in patients at risk should be mandatory. We aimed to assess the cardiovascular safety of abiraterone acetate in a real-world series of mCRPC patients treated at our institution.
Real

Introduction
In metastatic castration-resistant prostate cancer (mCRPC), abiraterone acetate has been shown to prolong patient survival [1, 2] and became a referral treatment both in a pre-and post-docetaxel setting. However, sequential strategy and agents used should be tailored to patient characteristics. Of note, a large proportion of metastatic prostate cancer (mPC) patients is represented by elderly patients usually typified by the presence of frailty and cardiovascular comorbidities [3] , that could affect prognosis independently from the outcomes of prostate cancer [4] . As a consequence, the evaluation of cardiovascular risk for each treatment option should be mandatory. Due to its action of lowering testosterone by inhibition of CYP-17, abiraterone acetate could lead to a mineralocorticoid excess mediated by a rebound upregulation of ACTH levels, raising the global cardiovascular risk [5] . Despite the favorable tolerability profile of abiraterone in mCRPC patients, a remarkable percentage of adverse events (AEs) potentially worsening cardiovascular risk have been reported in pivotal phase III studies (i.e. fluid retention, hypokalemia, hypertension and cardiac events) [6, 7] , and these evidences were corroborated by the results of a metanalysis assessing the cardiovascular risk linked with new hormonal agents [8] .
Here we aim retrospectively to assess the cardiovascular safety of abiraterone acetate in a real-world series of mCRPC patients treated at the Fondazione IRCCS Istituto Nazionale dei Tumori of Milan.
Materials and methods
Patient population
We retrospectively included mCRPC patients with at least 1 active cardiovascular comorbidity or risk factor according to the European Society of Cardiology (ESC) guidelines [9] and who started a treatment with abiraterone acetate 1000 mg once daily plus prednisone 5 mg twice daily at the Fondazione IRCCS Istituto Nazionale dei Tumori of Milan from April 2011 to July 2012. The presence of the following cardiovascular comorbidities or risk factors was considered for patient inclusion: hypertension, ischemic heart disease, rhythm disorder, valvular disorder, stroke and peripheral vascular disease, diabetes and hyperglycemia, hypercholesterolemia, nutritional status (assessed using body mass index) and smoking history. All patients should have received at least one docetaxel-based treatment and have an Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤2. Other key criteria for patient inclusion were: age ≥18 years old and absence of brain metastases or concomitant illnesses other than controlled cardiovascular diseases. Data regarding clinicopathological characteristics were retrieved from medical charts.
Cardiovascular and safety assessment
Cardiovascular risk was assessed using the ESC score risk chart [9] . As per clinical practice, baseline cardiovascular assessment was performed and included electrocardiogram (ECG), echocardiogram (ECHO), leftventricular ejection fraction (LVEF) and blood pressure. ECG, ECHO and LVEF were repeated at the end of treatment. Blood pressure was assessed daily. Data regarding cardiovascular history and cardiac AEs, defined according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 [10] , were retrieved from medical charts.
Statistical analysis
Safety data were analyzed by descriptive statistics as appropriate (mean, standard deviation, minimum and maximum values for continuous variables; absolute and relative frequencies for categorical variables).
Results
Patient characteristics
A total of 51 patients who started a treatment with abiraterone acetate at our institution from April 2011 to July 2012 and presented cardiovascular comorbidities or risk factors were included. Clinical and pathologic characteristics are summarized in Table 1 . Median age was 71 years (range 51-85), and 41% of patients received more than 1 previous line of hormonal therapy, while 49% received more than 1 line of docetaxel-based chemotherapy.
Cardiovascular comorbidities and risk factors
Overall, 9 out of 51 patients (18%) had an ESC score risk for major cardiovascular event ≥4%. Cardiovascular comorbidities and risk factors for the entire study population are shown in Table 2 . The most frequent cardiovascular comorbidity was hypertension (80%) followed by ischemic heart disease (12%) and stroke history (9%). The most prevalent risk factor was smoking (current or former, 69%) followed by overweight (39%) and hyperglycemia (30%). All patients received medications for cardiovascular comorbidities or risk factors, and 15 (29%) received a polytherapy. 
Safety profile of abiraterone acetate in patients with prostate cancer and cardiovascular comorbidities
Safety of abiraterone acetate
The median follow-up for safety observation was 36 months (range 12-48) while the median duration of abiraterone treatment was 16 months (range 9-21). No cardiac AEs (ECG abnormalities or LVEF decrease) were observed during the study period ( Table 3 ). The most frequent grade 1-2 AE reported was fluid retention (18%) followed by hypertension and asthenia (16%). Most frequent grade 3-4 AEs were asthenia and pruritus/rash. While a dose reduction was needed in 5 out of 51 patients (9.8%), no abiraterone discontinuation was due to toxicity. At the end of follow-up, 3 out of 51 patients (6%) were still receiving abiraterone while 12 (23%) were alive.
Discussion
In prostate cancer, selecting a safe and appropriate antitumor treatment in patients with cardiovascular comorbidities may be a hard challenge. The introduction of abiraterone acetate unquestionably improved clinical outcomes and treatment manageability in mCRPC [6] , but numerous doubts arose regarding its cardiovascular safety profile, due to the mechanism of action and characteristic toxicity [11] . Here we have shown that, in a retrospective series of 51 mCRPC patients with cardiovascular comorbidities or risk factors, long-term exposure to abiraterone acetate in a post-docetaxel setting did not result in a clinically relevant incident of cardiac or cardiovascular AEs. In particular, in line with previous reports [12] , no ECG abnormalities were observed, and no decrease in left ventricular function occurred during abiraterone treatment. Notably, long-term follow-up did not show any cardiovascular impairment, even in patients with clinically-impacting cardiovascular comorbidities (i.e., ischemic heart disease or rhythm disorders). It has been reported that androgen synthesis inhibitors used as second-line agents in mCRPC after docetaxel cause a significant increase in risk for mineralocorticoid-related AEs due to elevated mineralocorticoid secretion [11] [12] [13] . Linked to this effect, the AEs most frequently reported in our study were fluid retention and hypertension. Notably, hypertension had an incidence comparable to that previously reported in the same setting (11%) in the phase III study COU-AA-301 [6] while fluid retention had a lower incidence (18% in our series vs 33% in the COU-AA-301 study). It is clear that balancing the risks and effectiveness of androgen deprivation therapy remains an open question in mCRPC [14] [15] [16] . In alignment with data from several reports showing a very low incidence of grade 3-4 cardio- Clearly, the retrospective nature of the study, the small number of patients included and the lack of a control group limits the power of our observations. Thus, large multicentric, prospective trials are needed to corroborate our findings. Moreover, two large studies, the LATITUDE trial and the STAMPEDE trial, recently supported the use of abiraterone acetate as a treatment option for metastatic castration-naive prostate cancer (mCNPC) but showed an incidence of mineralocorticoid-related AEs even higher than that reported in mCRPC [21, 22] . Certainly, the assessment of the safety profile of abiraterone acetate in the presence of cardiovascular comorbidities or risks is essential in this setting.
In conclusion, abiraterone acetate seems to be safe in mCRPC patients with cardiovascular comorbidities or risk factors in the post-docetaxel setting. Further studies are needed to confirm our findings and to explore the manageability of abiraterone acetate administration in patients with mCRPC in the pre-docetaxel setting and in mCNPC.
